(Q37206628)

English

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

scientific article published on 16 May 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

multicenter clinical trial

0 references

0 references

ankylosing spondylitis

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Won Park

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Pawel Hrycaj

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Slawomir Jeka

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Volodymyr Kovalenko

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Grygorii Lysenko

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Pedro Miranda

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Helena Mikazane

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sergio Gutierrez-Ureña

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

MieJin Lim

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Yeon-Ah Lee

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sang Joon Lee

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

HoUng Kim

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Dae Hyun Yoo

13

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jürgen Braun

14

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

16 May 2013

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

72

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1605-1612

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

9 September 2017

The role of biosimilars in the treatment of rheumatic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

9 September 2017

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

9 September 2017

Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

9 September 2017

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

9 September 2017

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

9 September 2017

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

9 September 2017

Clinical pharmacokinetics and use of infliximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

9 September 2017

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

9 September 2017

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

9 September 2017

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

9 September 2017

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

9 September 2017

Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

3 September 2018

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786643

3 September 2018

Evaluating equivalence and noninferiority trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23687259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23687259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/23687259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23687259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23687259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23687259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23687259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2012-203091

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37206628&oldid=1543928187"